Marcelo Fiori Marchiori
Overview
Explore the profile of Marcelo Fiori Marchiori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dos Santos Moreira N, Lima J, Marchiori M, Carvalho I, Sakamoto-Hojo E
J Alzheimers Dis Rep
. 2022 May;
6(1):177-193.
PMID: 35591949
Alzheimer's disease (AD) is a slowly progressive neurodegenerative disease conceptualized as a continuous process, ranging from mild cognitive impairment (MCI), to the mild, moderate, and severe clinical stages of AD...
2.
Canassa-DeLeo T, Campo V, Rodrigues L, Marchiori M, Fuzo C, Brigido M, et al.
Glycoconj J
. 2019 Dec;
37(1):77-93.
PMID: 31823246
Dystroglycanopathies are diseases characterized by progressive muscular degeneration and impairment of patient's quality of life. They are associated with altered glycosylation of the dystrophin-glycoprotein (DGC) complex components, such as α-dystroglycan...
3.
Marchiori M, Iossi G, Bortot L, Dias-Baruffi M, Campo V
Carbohydr Res
. 2018 Nov;
472:23-32.
PMID: 30453095
α-Dystroglycan (α-DG) mucins are essential for maintenance of the structural and functional stability of the muscle fiber and, when hypoglycosylated, they are directly involved in pathological processes such as dystroglycanopathies....
4.
Campo V, Marchiori M, Carvalho I
Curr Top Med Chem
. 2018 May;
18(5):382-396.
PMID: 29741138
Chagas disease is still a worldwide threat, with estimated 6 to 7 million infected people, mainly in Latin America. Current treatments still rely only on benznidazol and nifurtimox, drugs with...
5.
Marchiori M, Riul T, Bortot L, Andrade P, Junqueira G, Foca G, et al.
Bioorg Med Chem
. 2017 Oct;
25(21):6049-6059.
PMID: 29032929
The synthesis of the O-3 triazole-linked galactosyl arylsulfonamides 1-7 as potential inhibitors of Trypanosoma cruzi cell invasion is described. These target compounds were synthesized by Cu(I)-catalysed azide-alkyne cycloaddition reaction ('click...
6.
Campo V, Riul T, Bortot L, Martins-Teixeira M, Marchiori M, Iaccarino E, et al.
Chembiochem
. 2017 Jan;
18(6):527-538.
PMID: 28068458
This study presents the synthesis of the novel protected O-glycosylated amino acid derivatives 1 and 2, containing βGalNAc-SerOBn and βGalNAc-ThrOBn units, respectively, as mimetics of the natural Tn antigen (αGalNAc-Ser/Thr),...
7.
Campo V, Marchiori M, Rodrigues L, Dias-Baruffi M
Glycoconj J
. 2016 Aug;
33(6):853-876.
PMID: 27526114
Galectin-3 is associated with the development and malignancy of several types of tumor, mediating important tumor-related functions, such as tumorigenesis, neoplastic transformation, tumor cell survival, angiogenesis, tumor metastasis and regulation...
8.
Marchiori M, Pires Souto D, Bortot L, Pereira J, Kubota L, Cummings R, et al.
Bioorg Med Chem
. 2015 May;
23(13):3414-25.
PMID: 25975642
This work describes the synthesis of the 1,2,3-triazole amino acid-derived-3-O-galactosides 1-6 and the 1,2,3-triazole di-lactose-derived glycoconjugate 7 as potential galectin-3 inhibitors. The target compounds were synthesized by Cu(I)-catalyzed azide-alkyne cycloaddition...